Pfizer enters deal for targeted cancer drugs
This article was originally published in Scrip
Executive Summary
Pfizer signed a deal with a biotech startup to develop a new generation of targeted antibody drugs for cancer.
You may also be interested in...
AbbVie Partnership On CD71 Gives CytomX Big Upfront, Co-Promotion Potential
Antibody-drug conjugates have taken a back seat to cancer immunotherapy as the hot modality in oncology of late, but AbbVie Inc. and CytomX Therapeutics Inc. unveiled a partnership on April 20 to develop an ADC in a deal that CytomX cites as further validation of its Probody technology platform.
Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Bresch is looking to do a sizable deal
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.